BACKGROUND: Whether mitral valve repair during coronary artery bypass grafting (CABG) improves survival in patients with ischemic mitral regurgitation (MR) remains unknown. METHODS AND RESULTS: Patients with ejection fraction ≤35% and coronary artery disease amenable to CABG were randomized at 99 sites worldwide tomedical therapy with or without CABG. The decision to treat the mitral valve during CABG was left to the surgeon. The primary end point was mortality. Of 1212 randomized patients, 435 (36%) had none/trace MR, 554 (46%) had mild MR, 181 (15%) had moderate MR, and 39 (3%) had severe MR. In the medical arm, 70 deaths (32%) occurred in patients with none/trace MR, 114 (44%) in those with mild MR, and 58 (50%) in those with moderate to severe MR. In patients with moderate to severe MR, there were 29 deaths (53%) among 55 patients randomized to CABG who did not receive mitral surgery (hazard ratio versus medical therapy, 1.20; 95% confidence interval, 0.77-1.87) and 21 deaths (43%) among 49 patients who received mitral surgery (hazard ratio versus medical therapy, 0.62; 95% confidence interval, 0.35-1.08). After adjustment for baseline prognostic variables, the hazard ratio for CABG with mitral surgery versus CABG alone was 0.41 (95% confidence interval, 0.22-0.77; P=0.006). CONCLUSION: Although these observational data suggest that adding mitral valve repair to CABG in patients with left ventricular dysfunction and moderate to severe MR may improve survival compared with CABG alone or medical therapy alone, a prospective randomized trial is necessary to confirm the validity of these observations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
RCT Entities:
BACKGROUND: Whether mitral valve repair during coronary artery bypass grafting (CABG) improves survival in patients with ischemic mitral regurgitation (MR) remains unknown. METHODS AND RESULTS:Patients with ejection fraction ≤35% and coronary artery disease amenable to CABG were randomized at 99 sites worldwide to medical therapy with or without CABG. The decision to treat the mitral valve during CABG was left to the surgeon. The primary end point was mortality. Of 1212 randomized patients, 435 (36%) had none/trace MR, 554 (46%) had mild MR, 181 (15%) had moderate MR, and 39 (3%) had severe MR. In the medical arm, 70 deaths (32%) occurred in patients with none/trace MR, 114 (44%) in those with mild MR, and 58 (50%) in those with moderate to severe MR. In patients with moderate to severe MR, there were 29 deaths (53%) among 55 patients randomized to CABG who did not receive mitral surgery (hazard ratio versus medical therapy, 1.20; 95% confidence interval, 0.77-1.87) and 21 deaths (43%) among 49 patients who received mitral surgery (hazard ratio versus medical therapy, 0.62; 95% confidence interval, 0.35-1.08). After adjustment for baseline prognostic variables, the hazard ratio for CABG with mitral surgery versus CABG alone was 0.41 (95% confidence interval, 0.22-0.77; P=0.006). CONCLUSION: Although these observational data suggest that adding mitral valve repair to CABG in patients with left ventricular dysfunction and moderate to severe MR may improve survival compared with CABG alone or medical therapy alone, a prospective randomized trial is necessary to confirm the validity of these observations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
Authors: Michael D Diodato; Marc R Moon; Michael K Pasque; Hendrick B Barner; Nader Moazami; Jennifer S Lawton; Marci S Bailey; Tracey J Guthrie; Bryan F Meyers; Ralph J Damiano Journal: Ann Thorac Surg Date: 2004-09 Impact factor: 4.330
Authors: Francesca Bursi; Maurice Enriquez-Sarano; Vuyisile T Nkomo; Steven J Jacobsen; Susan A Weston; Ryan A Meverden; Véronique L Roger Journal: Circulation Date: 2005-01-17 Impact factor: 29.690
Authors: Eric J Velazquez; Kerry L Lee; Marek A Deja; Anil Jain; George Sopko; Andrey Marchenko; Imtiaz S Ali; Gerald Pohost; Sinisa Gradinac; William T Abraham; Michael Yii; Dorairaj Prabhakaran; Hanna Szwed; Paolo Ferrazzi; Mark C Petrie; Christopher M O'Connor; Pradit Panchavinnin; Lilin She; Robert O Bonow; Gena Roush Rankin; Robert H Jones; Jean-Lucien Rouleau Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: G A Lamas; G F Mitchell; G C Flaker; S C Smith; B J Gersh; L Basta; L Moyé; E Braunwald; M A Pfeffer Journal: Circulation Date: 1997-08-05 Impact factor: 29.690
Authors: Benjamin H Trichon; G Michael Felker; Linda K Shaw; Christopher H Cabell; Christopher M O'Connor Journal: Am J Cardiol Date: 2003-03-01 Impact factor: 2.778
Authors: Benjamin H Trichon; Donald D Glower; Linda K Shaw; Christopher H Cabell; Kevin J Anstrom; G Michael Felker; Christopher M O'Connor Journal: Circulation Date: 2003-09-09 Impact factor: 29.690
Authors: Paul A Grayburn; Lilin She; Brad J Roberts; Krzysztof S Golba; Krzysztof Mokrzycki; Jaroslaw Drozdz; Alexander Cherniavsky; Roman Przybylski; Krzysztof Wrobel; Federico M Asch; Thomas A Holly; Haissam Haddad; Michael Yii; Gerald Maurer; Irving Kron; Hartzell Schaff; Eric J Velazquez; Jae K Oh Journal: Am J Cardiol Date: 2015-06-25 Impact factor: 2.778
Authors: Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler Journal: N Engl J Med Date: 2014-11-18 Impact factor: 91.245
Authors: Bart S Ferket; Vinod H Thourani; Pierre Voisine; Samuel F Hohmann; Helena L Chang; Peter K Smith; Robert E Michler; Gorav Ailawadi; Louis P Perrault; Marissa A Miller; Karen O'Sullivan; Stephanie L Mick; Emilia Bagiella; Michael A Acker; Ellen Moquete; Judy W Hung; Jessica R Overbey; Anuradha Lala; Margaret Iraola; James S Gammie; Annetine C Gelijns; Patrick T O'Gara; Alan J Moskowitz Journal: J Thorac Cardiovasc Surg Date: 2019-07-02 Impact factor: 5.209